enGene (ENGN) to Release Earnings on Wednesday

Key Points

• enGene (NASDAQ:ENGN) is set to release its Q3 2025 earnings on September 10th, with analysts predicting an expected loss of ($0.5084) per share.
• The company's last earnings report on June 10th showed a loss of ($0.51) EPS, missing analysts' expectations.
• enGene's shares opened at $4.80 and the company has a market capitalization of $245.28 million.

enGene (NASDAQ:ENGN - Get Free Report) is expected to release its Q3 2025 results before the market opens on Wednesday, September 10th. Analysts expect enGene to post earnings of ($0.5084) per share for the quarter. Interested persons can find conference call details on the company's upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, September 9, 2025 at 9:30 AM ET.

enGene (NASDAQ:ENGN - Get Free Report) last issued its earnings results on Tuesday, June 10th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.03). On average, analysts expect enGene to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

enGene Price Performance

Shares of NASDAQ ENGN opened at $4.80 on Wednesday. The company has a quick ratio of 12.66, a current ratio of 12.66 and a debt-to-equity ratio of 0.09. enGene has a 52 week low of $2.65 and a 52 week high of $11.00. The firm has a 50-day simple moving average of $3.83 and a 200-day simple moving average of $4.15. The stock has a market capitalization of $245.28 million, a price-to-earnings ratio of -2.91 and a beta of -0.39.

Institutional Investors Weigh In On enGene

An institutional investor recently bought a new position in enGene stock. Paloma Partners Management Co acquired a new stake in enGene Holdings Inc. (NASDAQ:ENGN - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,319 shares of the company's stock, valued at approximately $38,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.